MAP1LC3A and metabolic dysfunction-associated steatotic liver disease: This reduced MAP1LC3A expression is reflected in patient NAFLD livers, where patient samples exhibit dramatically low expression of MAP1LC3A (Fig. 8A bottom row) with a few birefringent LC-HLDs (Fig. 8A n).